ZA201005223B - Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars - Google Patents

Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars

Info

Publication number
ZA201005223B
ZA201005223B ZA2010/05223A ZA201005223A ZA201005223B ZA 201005223 B ZA201005223 B ZA 201005223B ZA 2010/05223 A ZA2010/05223 A ZA 2010/05223A ZA 201005223 A ZA201005223 A ZA 201005223A ZA 201005223 B ZA201005223 B ZA 201005223B
Authority
ZA
South Africa
Prior art keywords
connexin
polynucleotides
abnormal
treatment
excessive scars
Prior art date
Application number
ZA2010/05223A
Other languages
English (en)
Inventor
David L Becker
Colin R Green
Bradford J Duft
Original Assignee
Coda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coda Therapeutics Inc filed Critical Coda Therapeutics Inc
Publication of ZA201005223B publication Critical patent/ZA201005223B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
ZA2010/05223A 2007-12-21 2010-07-21 Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars ZA201005223B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US887707P 2007-12-21 2007-12-21
PCT/US2008/014028 WO2009085277A2 (en) 2007-12-21 2008-12-22 Treatment of abnormal or excessive scars

Publications (1)

Publication Number Publication Date
ZA201005223B true ZA201005223B (en) 2011-09-28

Family

ID=40824960

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/05223A ZA201005223B (en) 2007-12-21 2010-07-21 Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars

Country Status (7)

Country Link
US (1) US20110130710A1 (enExample)
EP (1) EP2252690A2 (enExample)
JP (2) JP2011507862A (enExample)
AU (1) AU2008343758A1 (enExample)
CA (1) CA2710388A1 (enExample)
WO (1) WO2009085277A2 (enExample)
ZA (1) ZA201005223B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2662088A3 (en) 2005-02-03 2014-02-19 Coda Therapeutics Limited Anti-connexin compounds and uses thereof
AU2008335718A1 (en) * 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
US8975237B2 (en) 2007-12-21 2015-03-10 Coda Therapeutics, Inc. Treatment of fibrotic conditions
CN104271142B (zh) 2012-03-01 2017-07-04 福斯特斯特林研究公司 含有α连接蛋白C‑末端(ACT)肽的局部凝胶
US10576037B2 (en) * 2012-03-14 2020-03-03 MAM Holdings of West Florida, L.L.C. Compositions comprising placental collagen for use in wound healing
CN104736709A (zh) 2012-03-27 2015-06-24 科达治疗公司 基于钙粘蛋白调节的组合物和治疗
US20140072613A1 (en) * 2012-09-10 2014-03-13 Cynthia Lander Compositions and Methods for Treating Cutaneous Scarring
JP6683686B2 (ja) 2014-08-22 2020-04-22 オークランド ユニサービシーズ リミティド チャネル調節剤
HK1247622A1 (zh) 2015-03-02 2018-09-28 180 Therapeutics Lp 利用il-33拮抗剂来治疗局部纤维化的方法
WO2016149194A1 (en) 2015-03-13 2016-09-22 MAM Holdings of West Florida, L.L.C. Collagen compositions and uses for biomaterial implants
WO2018199777A1 (en) 2017-04-28 2018-11-01 Auckland Uniservices Limited Methods of treatment and novel constructs
WO2019005643A1 (en) * 2017-06-26 2019-01-03 Next Science IP Holdings Pty Ltd METHOD OF TREATING PATHOLOGIES OF COLLAGEN FIBERS
WO2019152110A1 (en) * 2018-01-31 2019-08-08 Kci Usa, Inc. Antimicrobial composition, dressing, dressing components, and method
EP4232157A4 (en) 2020-10-22 2024-08-28 Xequel Bio, Inc. PEPTIDE FORMULATIONS AND ASSOCIATED OPHTHALMIC USES

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1322714C (en) * 1986-11-14 1993-10-05 Harry N. Antoniades Wound healing and bone regeneration
US5004810A (en) * 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
US5166195A (en) * 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
GB9206861D0 (en) * 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
US6566339B1 (en) * 1995-08-04 2003-05-20 Renovo Limited Pharmaceutical composition
GB2304047A (en) * 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
ES2293137T3 (es) * 1995-10-11 2008-03-16 Novartis Vaccines And Diagnostics, Inc. Combinacion de pdgf, kgf,igf e igfbp para curacion de heridas.
IT1294967B1 (it) * 1996-10-09 1999-04-23 Ist Farmacoterapico It Spa Composizione immunogenica da tlp
WO1998021358A1 (en) * 1996-11-15 1998-05-22 University Of Massachusetts Huntingtin-related therapeutics and bioassay
GB9702943D0 (en) * 1997-02-13 1997-04-02 Univ Manchester Wound healing
US5965618A (en) * 1997-11-17 1999-10-12 Perricone; Nicholas V. Treatment of scar tissue using lipoic acid
US6855505B2 (en) * 1998-06-26 2005-02-15 Renovo Limited Method for quantifying TGF-β
CA2361251C (en) * 1999-01-27 2011-03-08 David L. Becker Formulations comprising antisense nucleotides to connexins
GB9903598D0 (en) * 1999-02-18 1999-04-07 Univ Manchester Connective tissue healing
US7229822B1 (en) * 2000-02-29 2007-06-12 Univ Columbia Melanoma differentation associated gene-5 and vectors and cells containing same
US7186802B2 (en) * 2000-08-15 2007-03-06 Immunex Corporation Claudin polypeptides
US20050119211A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
NZ544031A (en) * 2003-06-09 2008-08-29 Univ Northwestern Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
JP5838017B2 (ja) * 2003-12-03 2015-12-24 コーダ セラピューティクス， インコーポレイテッド コネキシンに対して標的化されたアンチセンス化合物およびその使用方法
JP5097891B2 (ja) * 2005-09-20 2012-12-12 株式会社ポーラファルマ 皮膚外用剤
JP5960944B2 (ja) * 2006-11-15 2016-08-02 コーダ セラピューティクス， インコーポレイテッド 創傷治癒のための改善された方法および組成物
EP2340309A2 (en) * 2008-09-22 2011-07-06 Rxi Pharmaceuticals Corporation Neutral nanotransporters

Also Published As

Publication number Publication date
US20110130710A1 (en) 2011-06-02
WO2009085277A3 (en) 2009-11-26
CA2710388A1 (en) 2009-07-09
JP2011507862A (ja) 2011-03-10
WO2009085277A2 (en) 2009-07-09
AU2008343758A1 (en) 2009-07-09
EP2252690A2 (en) 2010-11-24
JP2015057431A (ja) 2015-03-26

Similar Documents

Publication Publication Date Title
ZA201005221B (en) Use of anti-connexin polynucleotides and peptides for the treatment of abnormal or excessive scars
SI2252300T1 (sl) Uporaba 2,4-pirimidindiaminov za zdravljenje ateroskleroze
PL2154969T3 (pl) Leczenie synukleinopatii
PL2205273T3 (pl) Zastosowanie zmodyfikowanych komórek w leczeniu stwardnienia rozsianego
HUE059861T2 (hu) N-Szubsztituált 2,5-dioxo-azolin vegyületek a rák kezelésében való felhasználásra
PL2209395T3 (pl) Urządzenie do traktowania włosów parą
ZA201005218B (en) Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of orthopedic conditions
ZA201002764B (en) Benzodiazepinone compounds useful in the treatment of skin conditions
EP2066246A4 (en) SKIN TREATMENT TOOL
IL198166A0 (en) Electrolytic tissue treatment devices
EP2184598A4 (en) FABRIC PIECE TREATMENT DEVICE
ZA201005220B (en) Use of anti-connexin polynucleotides for the treatment of surgical adhesions
ZA201005215B (en) Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of surgical adhesions
ZA201003425B (en) 5-cyano-thienopyridines for the treatment of tumors
GB2451889B (en) Apparatus for treating the skin with steam
IL206277A0 (en) 1,2,4-oxadiazole compounds for the treatment of autoimmune diseases
PL2209458T3 (pl) Kompozycje do traktowania skóry
GB0810364D0 (en) Improved effluent treatment
GB0909297D0 (en) Composition for the treatment of skin conditions
IL207965A (en) Compounds to treat or prevent pain
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
EP1968591A4 (en) TREATMENT OF SYNUCLEINOPATHIES
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
PL1945243T3 (pl) Zastosowanie kalcytoniny w leczeniu rzs
GB0814043D0 (en) The treatment of skin disorders